Moshe Sade-Feldman

Title: Moshe Sade-Feldman: Innovator in Cancer Immunotherapy

Introduction

Moshe Sade-Feldman is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of cancer immunotherapy, particularly through his innovative research and patented methods. With a total of 2 patents, Sade-Feldman is recognized for his work in understanding and improving cancer treatment strategies.

Latest Patents

Sade-Feldman's latest patents include groundbreaking methods and compositions related to CD8+ tumor infiltrating lymphocyte subtypes and their gene signatures. The first patent focuses on CD8+ tumor infiltrating lymphocytes that comprise gene signatures associated with responses to immunotherapy treatment. This patent outlines methods and compositions for utilizing these gene signatures, specifically in relation to checkpoint blockade therapy. The second patent addresses resistance to checkpoint blockade therapy, providing methods for determining resistance in cancer patients and assigning appropriate treatments based on gene expression analysis.

Career Highlights

Throughout his career, Moshe Sade-Feldman has worked with esteemed organizations such as The General Hospital Corporation and The Broad Institute, Inc. His work has significantly advanced the understanding of immune responses in cancer therapy, contributing to the development of more effective treatment options for patients.

Collaborations

Sade-Feldman has collaborated with notable colleagues, including Nir Hacohen and Keren Yizhak. These partnerships have fostered a collaborative environment that enhances research and innovation in the field of cancer immunotherapy.

Conclusion

Moshe Sade-Feldman's contributions to cancer immunotherapy through his patents and collaborations highlight his role as a key innovator in the field. His work continues to influence the development of effective cancer treatments, showcasing the importance of research and innovation in healthcare.